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Severe neutrophilia caused by renal cell carcinoma secreting granulocyte colony-stimulating factor (G-CSF)
is a rare manifestation of renal cancer. A 70-year-old woman presented with a 2-year history of severe anemia,
severe neutrophilia and elevated serum G-CSF, which completely resolved after radical nephrectomy. Histologic
study revealed a histologically high-grade, stage pT1N0M0 renal cell carcinoma. Serum G-CSF level was elevated
preoperatively and returned to normal postoperatively. Immunohistochemical study of the tumor tissue using
anti-G-CSF monoclonal antibody revealed positive staining in the cancer cells. Careful follow-up of white
blood cell count and physical examination for neck lymph node enlargement led to the timely identification
of tumor recurrence 17 months after surgery, which resulted in prompt and successful salvage immunotherapy.
In this case, G-CSF appeared to contribute to the leukocytosis, as both serum G-CSF level and white blood
cell count closely correlated with the clinical tumor growth. White blood cell count should be closely monitored
as an indicator of disease activity in patients with G-CSF-producing renal cell carcinoma. [ J Formos Med Assoc
2006;105(5):414–417]
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Granulocyte colony-stimulating factor (G-CSF)-
induced leukemoid reaction is a rare paraneo-
plastic syndrome in renal cell carcinoma, with a
poor prognosis. Although rare, it has also been
reported in several other malignancies, such as
bladder cancer,1 lung cancer,2 melanoma,3 hepato-
ma4 and glioblastoma.5 We report a patient with
renal cell carcinoma, who presented with severe
neutrophilia. G-CSF production by the tumor was
shown by immunohistochemical analysis.
Case Report
This 70-year-old woman had a 9-year history of
type 2 diabetes mellitus and a 2-year history of
anemia and leukocytosis of unknown cause. A
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right renal tumor was found at another hospital,
and she visited our hospital for a second opinion
in November 2001. Computed tomography (CT)
showed a 5 × 4 × 4 cm malignant right renal tu-
mor; however, she refused surgery at that time. In
April 2002, she presented with general malaise
and progressive shortness of breath for 5 days. A
hard, non-tender mass was palpated in the right
upper quadrant on bimanual examination. Ane-
mia (hemoglobin, 6.2 g/dL; normal, 11–16 g/dL)
and leukocytosis with neutrophilia (113,500/mm3
with 98% neutrophils; normal, 4000–9000/mm3)
were noted (Figure 1). Microscopic hematuria
(red blood cell count, 27/high power field) was
found on urinalysis. There was no evidence of foci
of infection or cardiac illness. CT demonstrated
progressive enlargement of the right renal tumor
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the development of mature neutrophils.6 G-CSF has
been shown to have therapeutic value in bone
marrow dysfunction and is widely used to reduce
the duration and severity of neutropenia in chemo-
therapy.6,7 Several non-hematologic malignancies
producing G-CSF from different organs presenting
with leukemoid reaction have been reported. The
prognosis in these cases was generally poor with
(7 × 6 × 5 cm). Bone marrow needle biopsy re-
vealed a myeloid/erythroid ratio of 10:1 without
evidence of malignancy. Right radical nephrecto-
my was performed.
Preoperative serum G-CSF measured by
enzyme-linked immunosorbent assay was 471.4
pg/mL (normal, 2.6–32.0 pg/mL), which dramati-
cally dropped to 15.4 pg/mL on postoperative day
10. Pathologic examination revealed a histologi-
cally high-grade, stage T1N0M0 conventional re-
nal cell carcinoma that was positive for anti-G-CSF
monoclonal antibody (Chugai Pharmaceutical
Co Ltd, Tokyo, Japan) in formalin-fixed, paraffin-
embedded specimens (Figures 2A and B). The pa-
tient soon recovered postoperatively; hemoglobin
was 10.6 g/dL and white blood cell count (WBC)
was 6090/mm3 with normal differential count
on postoperative day 9. The clinical course and
changes in WBC and values of serum G-CSF are
illustrated in Figure 1.
In September 2003, physical examination at
the outpatient department revealed a 2.5 × 2.5 cm,
fixed, non-tender lymph node on the left aspect of
the neck with simultaneous leukocytosis (27,900/
mm3 with 94% neutrophils). The resected cervical
lymph node was histologically consistent with the
renal cell carcinoma, with strong positive staining
using anti-G-CSF antibody (Figures 2C and D).
WBC dropped to 13,100/mm3 with 81% neutro-
phils postoperatively. After 8 months of salvage
immunotherapy with the combination of inter-
feron-_ (12 × 106 IU per week, intramuscular
injection) and interleukin-2 (18 × 106 IU per week,
subcutaneous injection), WBC returned to nor-
mal (Figure 1). The patient had no evidence of
malignancy, leukocytosis or anemia during 12
months of follow-up with physical examination,
chest X-ray, abdominal CT, bone scan and com-
plete blood cell counts.
Discussion
G-CSF is a cytokine that regulates the proliferation
and differentiation of hematopoietic progenitor
cells, and is particularly important in promoting
Figure 2. Renal cell carcinoma (conventional/granular cell type). (A) The tumor cells of
the kidney show abundant acidophilic and granular cytoplasm with nuclei of high grade
atypia (hematoxylin & eosin, × 200). (B) The cytoplasm is immunopositive for anti-
granulocyte colony-stimulating factor (G-CSF) monoclonal antibody (× 400). (C) Tumor
cells obtained from neck biopsy show a similar morphology (hematoxylin & eosin,
× 200). (D) Strong expression of anti-G-CSF antibody in the neck tumor by immunohis-
tochemistry (× 400).
Figure 1. Clinical course and changes in leukocyte count (WBC) and serum granulocyte
colony-stimulating factor (G-CSF).
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a virulent clinical course,1–5 which may have been
attributable to the G-CSF enhancing autocrine
growth of these tumors.1,8 The diagnostic criteria
for G-CSF-producing malignancies include: marked
leukocytosis with predominant mature neutro-
phils, elevated serum G-CSF, positive immunohis-
tochemical staining of tumor cells with anti-G-CSF
antibody, and elevated WBC and serum G-CSF re-
turning to normal after tumor removal. This case
is fully consistent with these criteria.9,10
This patient presented with a 2-year history of
paraneoplastic syndromes, including leukocytosis,
anemia and related symptoms with a high level of
serum G-CSF, all of which disappeared after sur-
gical resection of the tumor. G-CSF secreted by the
tumor apparently contributed to the leukocytosis
with an extremely high proportion of mature
neutrophils,6 and led to severe anemia via further
suppression of erythropoiesis. This phenomenon
was also demonstrated in an animal study by treat-
ing the mice with recombinant human G-CSF.11
Paraneoplastic syndromes, including hyperten-
sion, anemia, pyrexia, abnormal liver function,
hypercalcemia and polycythemia, are present in
20% of patients with renal cell carcinoma that au-
tonomously secrete different hormones.12,13 This
has led to the description of renal cell carcinoma
as an “internist’s tumor”. Nevertheless, leukemoid
reaction is a rare presentation in renal cell car-
cinoma. Our review of the literature revealed no
previous reports of renal cell carcinoma produc-
ing G-CSF from Western countries; however, two
immunohistochemically-identified cases were
reported from Japan, including one who died
within 20 days and another within 6 months
postoperatively, which illustrates the poor prog-
nosis in such cases.9
Although our patient initially refused opera-
tion, which led to a delay in management, the
enlarged tumor was still resectable when she re-
turned to the hospital 6 months later due to symp-
tom progression. Regular follow-up of complete
blood cell counts and careful physical examina-
tion, including palpation of cervical lymph nodes,
allowed the timely diagnosis of recurrent renal
cell carcinoma and planning of successful salvage
immunotherapy in this case. The outcome was
satisfactory postoperative tumor-free survival of
longer than 12 months at the last follow-up. As
shown in Figure 1, after the initial 2 months of
immunotherapy, WBC decreased to 3400/mm3,
which may reflect the side effect of leukopenia
resulting from immunotherapy.14 However, WBC
increased to a peak level of 23,000/mm3 during
continuous immunotherapy, suggesting the
secretion of G-CSF by the remaining tumor cells.
Finally, WBC declined to normal levels with con-
tinued therapy, suggesting that the tumor was
brought under control, and the immunotherapy
was, thus, stopped.
In conclusion, in cases of renal cell carcinoma
with remarkable leukocytosis and neutrophilia
but without obvious infection, the possibility of
G-CSF-induced leukemoid reaction should be con-
sidered. WBC should be closely followed as part
of the monitoring of disease activity.
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